Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Liliya Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2023-173499

Published: 2023

Journal Articles

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger

Blood (2022) 140 (Supplement 1): 9663–9664.

https://doi.org/10.1182/blood-2022-156889

Published: 2022

Journal Articles

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Blood (2022) 140 (3): 285–289.

https://doi.org/10.1182/blood.2022015832

Published: 2022

Includes: Supplemental data

Journal Articles

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2021) 138 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2021-152328

Published: 2021

Journal Articles

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Heinz Gisslinger, MD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, MD, Petr Dulicek, MD, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiří Mayer, Vera Yablokova, MD, Kurt Krejcy, MD, Victoria Empson, MSc, Hans C. Hasselbalch, MD, Robert Kralovics, PhD, Jean Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136973

Published: 2020

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Blood (2019) 134 (Supplement_1): 2591.

https://doi.org/10.1182/blood-2019-127253

Published: 2019

Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Blood (2019) 134 (Supplement_1): 4235.

https://doi.org/10.1182/blood-2019-129614

Published: 2019

Journal Articles

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 163.

https://doi.org/10.1182/blood-2018-163

Published: 2018

Journal Articles

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Arpad Illes, MD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, Professor, dr.MD, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2018) 132 (Supplement 1): 579.

https://doi.org/10.1182/blood-2018-99-118715

Published: 2018

Journal Articles

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Heinz Gisslinger, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, Liana Gercheva, MD PhD, Miklos Egyed, MD PhD, Viktor Rossiev, Petr Dulicek, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sicheva, Jiri Mayer, Prof, MD SCs, Vera Yablokova, Kurt Krejcy, PhD, Barbara Grohmann-Izay, MD MSc, Hans Carl Hasselbalch, MD Professor, DMSc, Robert Kralovics, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2017) 130 (Supplement 1): 320.

https://doi.org/10.1182/blood.V130.Suppl_1.320.320

Published: 2017

Journal Articles

Therapeutic Results in Patients with Hodgkin's Lymphoma Treated with Brentuximab Vedotin — Bulgarian Experience

Veselina S Goranova Marinova, MD PhD, Kalina Ignatova, MD, Penka Ganeva, MD, Emil Spasov, MD PhD, Ilina Micheva, MD PhD, Atanas Radinov, MD, Raya Petrova, MD, Gergana Tzvetkova, MD, Eugueni Hadzhiev, MD PhD, Stefan E Goranov, MD PhD DMSc, Liana Gercheva, MD PhD

Blood (2017) 130 (Supplement 1): 5193.

https://doi.org/10.1182/blood.V130.Suppl_1.5193.5193

Published: 2017

Journal Articles

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, MD, Christoph Klade, Pencho Georgiev, Aleksander Skotnicki, MD PhD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, Arpad Illes, MD PhD, Halyna Pylypenko, MD, Liliya Sivcheva, Jiri Mayer, MD, Barbara Grohmann-Izay, MD, Hans Hasselbalch, MD, Robert Kralovics, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 475.

https://doi.org/10.1182/blood.V128.22.475.475

Published: 2016

Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Blood (2014) 124 (21): 20.

https://doi.org/10.1182/blood.V124.21.20.20

Published: 2014

Journal Articles

Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Marina Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Françoise Huguet, MD, Ilaria Del Guidice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo

Blood (2010) 116 (21): 2449.

https://doi.org/10.1182/blood.V116.21.2449.2449

Published: 2010

Journal Articles

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Blood (2010) 116 (21): 2271.

https://doi.org/10.1182/blood.V116.21.2271.2271

Published: 2010

Journal Articles

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Andreas Engert, MD, Liana Gercheva, MD, PhD, Galina Pilipenko, MD, Tadeusz Robak, MD, PhD, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2010) 116 (21): 919.

https://doi.org/10.1182/blood.V116.21.919.919

Published: 2010

Journal Articles

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, MD, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Francoise Huguet, MD, Ilaria Del Giudice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo, MD

Blood (2009) 114 (22): 2367.

https://doi.org/10.1182/blood.V114.22.2367.2367

Published: 2009

Journal Articles

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Andreas Engert, MD, Liana Gercheva, MD, Tadeusz Robak, Pilipenko Galina, Jingyang Wu, MS, Cynthia A. Sirard, MD, Thomas Elter, MD

Blood (2009) 114 (22): 537.

https://doi.org/10.1182/blood.V114.22.537.537

Published: 2009

Journal Articles

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

Wolfgang Ulrich Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna Liberati, Javier Loscertales, Roul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, Liana Gercheva, Stefan Goranov, MD, Martin Becker, Klaus Hoeffken, Francoise Huguet, Robert Foa, MD, Karlheinz Merkle, Marco Montillo

Blood (2008) 112 (11): 2091.

https://doi.org/10.1182/blood.V112.11.2091.2091

Published: 2008

NARROW

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in Polycythemia Vera: Two-Year Results from the First Prospective Randomized Controlled Trial

Therapeutic Results in Patients with Hodgkin's Lymphoma Treated with Brentuximab Vedotin — Bulgarian Experience

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only